About Us Careers Contact Us

Home
Products
Isotope Labeled Active Pharmaceutical Ingredients (APIs)
Alectinib-[d5]

Inquiry List

* Name:
* Phone:
* Service & Products of Interested: [Isotope Labeled Active Pharmaceutical Ingredients (APIs)] Alectinib-[d5] (1616374-15-2)
Project Description:
* Quantity
* Email:
* Organization We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
* Verification Code:

Our Highlights

Optimal Prices
Buying products on this site guarantees the best price
Flexible Batches
Flexible batch size to meet different needs of global customers
Prompt Delivery
Warehouses in multiple cities to ensure timely delivery
Quality Assurance
Strict process parameter control to ensure product quality
One-to-one Customization
One-to-one custom synthesis for special structural needs

Application Area

Environmental

Stable isotope-labeled compounds are used as environmental pollutant standards for the detection of air, water, soil, sediment and food.

Clinical diagnostic

In addition to treating various diseases, isotopes are used for imaging, diagnosis, and newborn screening.

Organic Chemistry

Small molecule compounds labeled with stable isotopes can be used as chemical reference for chemical identification, qualitative, quantitative, detection, etc. Various types of NMR solvents can be used to study the structure, reaction mechanism and reaction kinetics of compounds.

Metabolic Research

Stable isotope labeling allows researchers to study metabolic pathways in vivo in a safe manner.

Alectinib-[d5]

Inquiry

General Information
Catalog: BLP-003248
CAS: 1616374-15-2
Molecular Formula: C30H29D5N4O2
Molecular Weight: 487.65

Chemical Structure

Description	Labelled Alectinib. Alectinib, marketed as Alecensa, is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib has a low potential for interactions. While it is metabolised by the liver enzyme CYP3A4, and blockers of this enzyme accordingly increase its concentrations in the body, they also decrease concentrations of the active metabolite M4, resulting in only a small overall effect. Conversely, CYP3A4 inducers decrease alectinib concentrations and increase M4 concentrations. Interactions via other CYP enzymes and transporter proteins cannot be excluded but are unlikely to be of clinical significance.
Synonyms	9-(ethyl-1,1,2,2,2-d5)-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-Benzo[b]carbazole-3-carbonitrile; Alectinib-d5
Related CAS	1256580-46-7 (unlabelled)
Purity	> 98%